[i] Marcellin P et al. HBsAg clearance continues to increase after the end of treatment with PEGASYS plus or minus lamivudine: 5-year follow-up study in patients with HBeAg-negative disease. Presented at: Asian Pacific Association for the Study of the Liver (APASL); February 13-16, 2009; Hong Kong, China.
[ii] Lau GKK et al. HBsAg decline in patients treated with PEGASYS and its association with post-treatment response in HBeAg positive chronic hepatitis B. Presented at: Asian Pacific Association for the Study of the Liver (APASL); February 13-16, 2009; Hong Kong, China.
[iii] Marcellin P et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a (40KD) with or without lamivudine: results of 4-year follow-up. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver (EASL); April 23-27, 2008; Milan, Italy.
[iv] Fattovich G et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol. 1998;93(6):896-900.
[v] Perrillo RP. Therapy of hepatitis B -- viral suppression or eradication? Hepatology. 2006;43(2 suppl 1):S182-S193.
[vi] Hoofnagle JH et al. Management of hepatitis B: summary of a clinical research group. Hepatology. 2007;45(4):1056-1075.
[vii] Ferruccio B et al. Use of the Elecsys(R) HBsAg II assay for simple and accurate quantification of HBsAg levels in sera of patients infected with HBV. Presented at: Asian Pacific Association for the Study of the Liver (APASL); February 13-16, 2009; Hong Kong, China.
[viii] Jidong J et al. Comparison of the sensitivity and specificity of the Elecsys(R) HBsAg II assay with other available assays in China for detection of HBsAg. Presented at: Asian Pacific Association for the Study of the Liver (APASL); February 13-16, 2009; Hong Kong, China.
[ix] Louisirirotchanakul S et al. Multiple sites for evaluation of the performance of the Elecsys(R) HBsAg II assay. Presented at: Asian Pacific Association for the Study of the Liver (APASL); February 13-16, 2009; Hong Kong, China.
Roche Group Media Relations, Corporate Communications, Phone: +41-61-688-8888 / e-mail: basel.mediaoffice@roche.com - Daniel Piller (Head) - Alexander Klauser - Valeria Passoni - Martina Rupp - Claudia Schmitt
